Potential Zoonotic Infection of Porcine Endogenous Retrovirus in Xenotransplantation
Porcine endogenous retrovirus (PERV) is considered the major biosafety issue in xenotransplantation. Several techniques have been employed for the analysis of the PERV status in the animal donor and for the assessment of PERV transmission/infection in the xenograft recipient. In this chapter, methods to assess the expression of PERV and the potential for PERV transmission from a donor animal are described in addition to the identification of relevant loci within the porcine genome.
PERV detection can be carried out using several techniques of which quantitative polymerase chain reaction (PCR) and RT-PCR are the most sensitive. However, other procedures can be employed such as detection of reverse transcriptase activity (i.e. viral replication) in the sample or immunostaining of the infected cells using an anti-PERV antibody. The PERV transmission assay has been described to identify the transmission phenotype of the pig donor, and subsequent risk from a donor. This assay can, therefore, direct the selection of the most suitable animal. Finally, it is important to determine the presence of critical PERV loci involved in transmission in the pig genome and compare between different animals. One of the methods for the analysis of these PERV integration sites is described.
Key wordsPorcine endogenous retrovirus Infection assay SYBR green-based quantitative PCR Reverse transcriptase assay In situ immunostaining Splinkerette
The authors’ PERV research has been funded by the European Sixth Framework Programme (Life Science, Genomics and Biotechnology for Health) funded project LSHB-CT-2006-037377.
- 1.FDA (2001) PHS guideline on infectious disease issues in xenotransplantation: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Xenotransplantation/ucm074727.htm
- 7.Boeke J, Stoye JP (1997) Retrotransposons, endogenous retroviruses, and the evolution of retroelement. In: Coffin JM, Hughes SH, Varmus HE (eds) Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 345–362Google Scholar
- 13.Wood JC, Quinn G, Suling KM, Oldmixon BA, Van Tine BA, Cina R, Arn S, Huang CA, Scobie L, Onions DE, Sachs DH, Schuurman HJ, Fishman JA, Patience C (2004) Identification of exogenous forms of human-tropic porcine endogenous retrovirus in miniature Swine. J Virol 78:2494–2501PubMedCrossRefGoogle Scholar
- 17.Garkavenko O, Wynyard S, Nathu D, Simond D, Muzina M, Muzina Z, Scobie L, Hector RD, Croxson MC, Tan P, Elliott BR (2008) Porcine endogenous retrovirus (PERV) and its transmission characteristics: a study of the New Zealand designated pathogen-free herd. Cell Transplant 17:1381–1388PubMedCrossRefGoogle Scholar
- 22.Paradis K, Langford G, Long Z, Heneine W, Sandstrom P, Switzer WM, Chapman LE, Lockey C, Onions D, Otto E (1999) Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science 285:1236–1241PubMedCrossRefGoogle Scholar
- 30.Wilson CA (2006) Porcine retrovirus. In: Straw BE, Zimmerman JJ, D’Allaire S, Taylor DJ (eds) Diseases of swine 9th edn. Blackwell Publishing, Ames, pp 545–550Google Scholar
- 31.Morrison TB, Weis JJ, Wittwer CT (1998) Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 24:954–958, 960, 962Google Scholar
- 33.Issa NC, Wilkinson RA, Griesemer A, Cooper DK, Yamada K, Sachs DH, Fishman JA (2008) Absence of replication of porcine endogenous retrovirus and porcine lymphotropic herpesvirus type 1 with prolonged pig cell microchimerism after pig-to-baboon xenotransplantation. J Virol 82:12441–12448PubMedCrossRefGoogle Scholar
- 38.Gabriel R, Eckenberg R, Paruzynski A, Bartholomae CC, Nowrouzi A, Arens A, Howe SJ, Recchia A, Cattoglio C, Wang W, Faber K, Schwarzwaelder K, Kirsten R, Deichmann A, Ball CR, Balaggan KS, Yanez-Munoz RJ, Ali RR, Gaspar HB, Biasco L, Aiuti A, Cesana D, Montini E, Naldini L, Cohen-Haguenauer O, Mavilio F, Thrasher AJ, Glimm H, von Kalle C, Saurin W, Schmidt M (2009) Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med 15:1431–1436PubMedCrossRefGoogle Scholar